facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
pcos I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim

to O
evaluate O
the O
impact O
of O
laser O
treatment O
on O
the O
severity O
of O
facial O
hirsutism O
and O
on O
psychological O
morbidity O
in O
women O
with O
pcos O
. O

a O
randomized O
controlled O
trial O
of O
five O
high O
- O
fluence O
treatments O
( O
intervention O
) O
vs O
. O
five O
low O
- O
fluence O
treatments O
( O
control O
) O
was O
performed O
over O
6 O
months O
in O
a O
national O
health O
service O
teaching O
hospital O
. O

subjects O
were O
88 O
women O
with O
facial O
hirsutism O
due O
to O
pcos O
recruited O
from O
hospital O
outpatient O
clinics O
and O
a O
patient O
support O
group O
in O
2001 O
- O
2002 O
. O

the O
main O
outcomes O
were O
self O
- O
reported O
severity O
of O
facial O
hair O
( O
measured O
on O
a O
scale O
of O
1 O
- O
10 O
) O
, O
depression O
, O
anxiety O
( O
measured O
on O
the O
hospital O
anxiety O
and O
depression O
scale O
) O
and O
quality O
of O
life O
( O
measured O
on O
the O
whoqol O
- O
bref O
) O
. O

laser B-Claim
treatment I-Claim
appeared I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
facial I-Claim
hair I-Claim
and I-Claim
time I-Claim
spent I-Claim
on I-Claim
hair I-Claim
removal I-Claim
as I-Claim
well I-Claim
as I-Claim
alleviating I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
in I-Claim
women I-Claim
with I-Claim
pcos I-Claim
. I-Claim

these B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim

despite B-Claim
considerable I-Claim
improvement I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
, I-Claim
the I-Claim
optimization I-Claim
of I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
remains I-Claim
an I-Claim
important I-Claim
issue I-Claim
. I-Claim

therefore O
, O
we O
performed O
a O
randomized O
, O
phase O
iii O
non O
- O
inferiority O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
( O
pt O
) O
with O
paclitaxel O
plus O
carboplatin O
( O
tc O
) O
in O
patients O
with O
advanced O
ovarian O
cancer O
. O

a O
total O
of O
798 O
patients O
with O
international O
federation O
of O
gynecology O
and O
obstetrics O
stage O
iib O
- O
iv O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
either O
pt O
or O
tc O
at O
3 O
- O
week O
intervals O
. O

the O
primary O
endpoint O
was O
the O
proportion O
of O
patients O
without O
progression O
at O
2 O
years O
. O

secondary O
endpoints O
included O
toxicity O
, O
response O
to O
treatment O
, O
quality O
of O
life O
, O
and O
overall O
and O
progression O
- O
free O
survival O
time O
. O

quality O
of O
life O
was O
evaluated O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
- O
of O
- O
life O
questionnaire O
( O
qlq O
) O
- O
c30 O
, O
version O
2 O
. O
0 O
. O

survival O
curves O
were O
calculated O
using O
the O
kaplan O
- O
meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
using O
the O
cox O
proportional O
hazards O
model O
. O

the B-Claim
tc I-Claim
regimen I-Claim
achieved I-Claim
comparable I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
pt I-Claim
regimen I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
tolerability I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
should I-Claim
, I-Claim
therefore I-Claim
, I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
important I-Claim
alternative I-Claim
for I-Claim
standard I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

the O
aim O
of O
this O
study O
was O
to O
compare O
the O
2 O
- O
year O
functional O
performance O
and O
quality O
of O
life O
in O
patients O
with O
operable O
squamous O
cell O
carcinoma O
of O
the O
esophagus O
, O
who O
have O
received O
either O
surgery O
or O
definitive O
chemoradiation O
( O
crt O
) O
. O

the O
functional O
outcomes O
and O
quality O
of O
life O
in O
patients O
receiving O
esophagectomy O
or O
definitive O
crt O
is O
uncertain O
. O

data O
were O
extracted O
from O
the O
database O
of O
a O
prospective O
randomized O
controlled O
trial O
that O
included O
patients O
with O
resectable O
mid O
or O
lower O
thoracic O
esophageal O
cancers O
. O

the O
patients O
were O
randomized O
to O
either O
standard O
esophagectomy O
or O
definitive O
crt O
. O

quality O
of O
life O
assessments O
were O
performed O
using O
the O
eortc O
qlq O
- O
c30 O
and O
qlq O
- O
oes24 O
modules O
. O

other O
functional O
assessments O
included O
pulmonary O
and O
eating O
functions O
. O

from O
july O
2000 O
to O
december O
2004 O
, O
a O
total O
of O
81 O
patients O
were O
enrolled O
into O
the O
study O
. O

surgery B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
short I-Claim
- I-Claim
term I-Claim
negative I-Claim
impact I-Claim
in I-Claim
some I-Claim
aspects I-Claim
of I-Claim
health I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
assessments I-Claim
but B-Claim
these I-Claim
changes I-Claim
became I-Claim
insignificant I-Claim
2 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim

however O
, O
crt B-Claim
was I-Claim
associated I-Claim
with I-Claim
progressive I-Claim
deteriorations I-Claim
in I-Claim
pulmonary I-Claim
function I-Claim
in I-Claim
the I-Claim
longer I-Claim
term I-Claim
. I-Claim

to O
observe O
the O
effect O
of O
tcm O
therapy O
for O
removing O
toxic O
substance O
and O
unblocking O
meridians O
on O
post O
- O
radiation O
quality O
of O
life O
( O
qof O
) O
in O
55 O
patients O
with O
lung O
cancer O
. O

all O
patients O
were O
randomly O
assigned O
to O
two O
groups O
, O
the O
55 O
patients O
in O
the O
treated O
group O
were O
treated O
with O
radiotherapy O
combined O
with O
the O
tcm O
therapy O
, O
and O
the O
53 O
in O
the O
control O
group O
were O
given O
radiotherapy O
alone O
. O

the O
clinical O
efficacy O
was O
evaluated O
by O
indexes O
including O
kps O
scores O
, O
qlq O
- O
c30 O
questionnaire O
, O
lc13 O
specific O
scale O
for O
lung O
cancer O
, O
evaluation O
criteria O
for O
tcm O
efficacy O
, O
the O
6 O
- O
min O
walking O
distance O
, O
and O
body O
weight O
, O
etc O
. O

tcm B-Claim
therapy I-Claim
for I-Claim
removing I-Claim
toxic I-Claim
substance I-Claim
and I-Claim
unblocking I-Claim
meridians I-Claim
can I-Claim
improve I-Claim
the I-Claim
post I-Claim
- I-Claim
radiation I-Claim
qol I-Claim
of I-Claim
patients I-Claim
with I-Claim
lung I-Claim
cancer I-Claim
to I-Claim
some I-Claim
extent I-Claim
. I-Claim

the O
averel O
trial O
[ O
a O
study O
of O
avastin O
( O
bevacizumab O
) O
in O
combination O
with O
herceptin O
( O
trastuzumab O
) O
/ O
docetaxel O
in O
patients O
with O
her2 O
- O
positive O
metastatic O
breast O
cancer O
] O
evaluated O
first O
- O
line O
bevacizumab O
- O
containing O
therapy O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
her2 O
) O
- O
positive O
locally O
recurrent O
/ O
metastatic O
breast O
cancer O
( O
lr O
/ O
mbc O
) O
. O

patients O
with O
measurable O
/ O
evaluable O
her2 O
- O
positive O
lr O
/ O
mbc O
who O
had O
not O
received O
trastuzumab O
or O
chemotherapy O
for O
lr O
/ O
mbc O
were O
stratified O
by O
prior O
adjuvant O
trastuzumab O
, O
prior O
( O
neo O
) O
adjuvant O
taxane O
, O
hormone O
receptor O
status O
, O
and O
measurable O
disease O
and O
were O
randomly O
assigned O
to O
receive O
docetaxel O
100 O
mg O
/ O
m O
( O
2 O
) O
plus O
trastuzumab O
8 O
mg O
/ O
kg O
loading O
dose O
followed O
by O
6 O
mg O
/ O
kg O
either O
with O
bevacizumab O
15 O
mg O
/ O
kg O
or O
without O
bevacizumab O
, O
all O
administered O
every O
3 O
weeks O
. O

the O
primary O
end O
point O
was O
progression O
- O
free O
survival O
( O
pfs O
) O
. O

additional O
end O
points O
included O
overall O
survival O
, O
response O
rate O
( O
rr O
) O
, O
safety O
, O
quality O
of O
life O
, O
and O
translational O
research O
. O

results O
baseline O
characteristics O
of O
the O
424 O
patients O
were O
balanced O
between O
treatment O
arms O
. O

most O
patients O
had O
visceral O
metastases O
, O
43 O
% O
had O
a O
disease O
- O
free O
interval O
less O
than O
12 O
months O
, O
and O
85 O
% O
had O
measurable O
disease O
. O

median O
follow O
- O
up O
was O
26 O
months O
. O

grade B-Claim
â‰¥ I-Claim
3 I-Claim
febrile I-Claim
neutropenia I-Claim
and I-Claim
hypertension I-Claim
were I-Claim
more I-Claim
common I-Claim
with I-Claim
bevacizumab I-Claim
- I-Claim
containing I-Claim
therapy I-Claim
. I-Claim

combining B-Claim
bevacizumab I-Claim
with I-Claim
docetaxel I-Claim
and I-Claim
trastuzumab I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
investigator I-Claim
- I-Claim
assessed I-Claim
pfs I-Claim
. I-Claim

the O
potential O
predictive O
value O
of O
plasma O
vegf O
- O
a O
is O
consistent O
with O
findings O
in O
her2 O
- O
negative O
lr O
/ O
mbc O
, O
warranting O
prospective O
evaluation O
. O

vinorelbine B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
. I-Claim

some B-Claim
studies I-Claim
have I-Claim
also I-Claim
suggested I-Claim
that I-Claim
gemcitabine I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
in I-Claim
such I-Claim
patients I-Claim
. I-Claim

we O
compared O
the O
effectiveness O
and O
toxicity O
of O
the O
combination O
of O
vinorelbine O
plus O
gemcitabine O
with O
those O
of O
each O
drug O
given O
alone O
in O
an O
open O
- O
label O
, O
randomized O
phase O
iii O
trial O
in O
elderly O
patients O
with O
advanced O
nsclc O
. O

patients O
aged O
70 O
years O
and O
older O
, O
enrolled O
between O
december O
1997 O
and O
november O
2000 O
, O
were O
randomly O
assigned O
to O
receive O
intravenous O
vinorelbine O
( O
30 O
mg O
/ O
m O
( O
2 O
) O
of O
body O
surface O
area O
) O
, O
gemcitabine O
( O
1200 O
mg O
/ O
m O
( O
2 O
) O
) O
, O
or O
vinorelbine O
( O
25 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
gemcitabine O
( O
1000 O
mg O
/ O
m O
( O
2 O
) O
) O
. O

all O
treatments O
were O
delivered O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
for O
a O
maximum O
of O
six O
cycles O
. O

the O
primary O
endpoint O
was O
survival O
. O

survival O
curves O
were O
drawn O
using O
the O
kaplan O
- O
meier O
method O
and O
analyzed O
by O
the O
mantel O
- O
haenszel O
test O
. O

secondary O
endpoints O
were O
quality O
of O
life O
and O
toxicity O
. O

of O
698 O
patients O
available O
for O
intention O
- O
to O
- O
treat O
analysis O
, O
233 O
were O
assigned O
to O
receive O
vinorelbine O
, O
233 O
to O
gemcitabine O
, O
and O
232 O
to O
vinorelbine O
plus O
gemcitabine O
. O

the B-Claim
combination I-Claim
of I-Claim
vinorelbine I-Claim
plus I-Claim
gemcitabine I-Claim
is I-Claim
not I-Claim
more I-Claim
effective I-Claim
than I-Claim
single I-Claim
- I-Claim
agent I-Claim
vinorelbine I-Claim
or I-Claim
gemcitabine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim

to O
evaluate O
the O
efficacy O
of O
a O
psychoeducational O
intervention O
in O
improving O
cancer O
- O
related O
fatigue O
. O

this O
randomized O
controlled O
trial O
involved O
109 O
women O
commencing O
adjuvant O
chemotherapy O
for O
stage O
i O
or O
ii O
breast O
cancer O
in O
five O
chemotherapy O
treatment O
centers O
. O

intervention O
group O
patients O
received O
an O
individualized O
fatigue O
education O
and O
support O
program O
delivered O
in O
the O
clinic O
and O
by O
phone O
over O
three O
- O
10 O
to O
20 O
- O
minute O
sessions O
1 O
week O
apart O
. O

instruments O
included O
a O
numeric O
rating O
scale O
assessing O
confidence O
with O
managing O
fatigue O
"""" O
; O
"""" O
11 O
- O
point O
numeric O
rating O
scales O
measuring O
fatigue O
at O
worst O
, O
average O
, O
and O
best O
"""" O
; O
"""" O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
fatigue O
and O
piper O
fatigue O
scales O
"""" O
; O
"""" O
the O
cancer O
self O
- O
efficacy O
scale O
"""" O
; O
"""" O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
c30 O
"""" O
; O
"""" O
and O
the O
hospital O
anxiety O
and O
depression O
scale O
. O

for O
each O
outcome O
, O
separate O
analyses O
of O
covariance O
of O
change O
scores O
between O
baseline O
( O
t1 O
) O
and O
the O
three O
follow O
- O
up O
time O
points O
( O
t2 O
, O
t3 O
, O
and O
t4 O
) O
were O
conducted O
, O
controlling O
for O
the O
variable O
' O
s O
corresponding O
baseline O
value O
. O

preparatory B-Claim
education I-Claim
and I-Claim
support I-Claim
has I-Claim
the I-Claim
potential I-Claim
to I-Claim
assist I-Claim
women I-Claim
to I-Claim
cope I-Claim
with I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
in I-Claim
the I-Claim
short I-Claim
term I-Claim
. I-Claim

however B-Claim
, I-Claim
further I-Claim
research I-Claim
is I-Claim
needed I-Claim
to I-Claim
identify I-Claim
ways I-Claim
to I-Claim
improve I-Claim
the I-Claim
potency I-Claim
and I-Claim
sustainability I-Claim
of I-Claim
psychoeducational I-Claim
interventions I-Claim
for I-Claim
managing I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
. I-Claim

to O
evaluate O
the O
incidence O
and O
temporal O
resolution O
of O
dysuria O
after O
permanent O
prostate O
brachytherapy O
, O
and O
to O
identify O
predictors O
of O
brachytherapy O
- O
related O
dysuria O
. O

the O
study O
included O
130 O
patients O
with O
no O
history O
of O
transurethral O
resection O
of O
the O
prostate O
before O
treatment O
, O
who O
had O
brachytherapy O
on O
one O
of O
two O
prospective O
randomized O
trials O
, O
with O
explicitly O
planned O
and O
executed O
urethral O
- O
sparing O
techniques O
( O
100 O
- O
150 O
% O
minimum O
peripheral O
dose O
) O
using O
either O
103pd O
or O
125i O
for O
clinical O
t1c O
- O
t2c O
prostate O
cancer O
. O

the O
median O
follow O
- O
up O
was O
22 O
. O
6 O
months O
. O

an O
alpha O
- O
blocker O
was O
initiated O
either O
prophylactically O
2 O
weeks O
before O
implantation O
and O
continued O
at O
least O
until O
the O
international O
prostate O
symptom O
score O
( O
ipss O
) O
returned O
to O
normal O
, O
or O
withheld O
until O
the O
onset O
of O
significant O
brachytherapy O
- O
related O
urinary O
morbidity O
. O

dysuria O
was O
evaluated O
on O
a O
0 O
- O
10 O
scale O
, O
before O
brachytherapy O
and O
then O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
afterward O
, O
with O
a O
median O
of O
four O
dysuria O
questionnaires O
per O
patient O
. O

clinical O
, O
treatment O
and O
dosimetric O
variables O
evaluated O
included O
alpha O
- O
blocker O
, O
age O
, O
ipss O
before O
and O
the O
maximum O
after O
treatment O
, O
prostate O
volume O
on O
ultrasonography O
, O
hormonal O
status O
, O
supplemental O
radiotherapy O
, O
isotope O
, O
urethral O
dose O
, O
v O
( O
100 O
/ O
200 O
) O
, O
d90 O
, O
and O
time O
to O
obtaining O
a O
normal O
ipss O
. O

the O
maximum O
incidence O
of O
dysuria O
was O
85 O
% O
at O
1 O
month O
after O
brachytherapy O
, O
with O
subsequent O
resolution O
over O
time O
. O

dysuria B-Claim
is I-Claim
common I-Claim
after I-Claim
brachytherapy I-Claim
but I-Claim
is I-Claim
typically I-Claim
mild I-Claim
. I-Claim

prophylactic B-Claim
alpha I-Claim
- I-Claim
blockers I-Claim
gave I-Claim
significantly I-Claim
lower I-Claim
maximum I-Claim
dysuria I-Claim
scores I-Claim
but B-Claim
did I-Claim
not I-Claim
affect I-Claim
the I-Claim
time I-Claim
to I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

the B-Claim
maximum I-Claim
ipss I-Claim
after I-Claim
the I-Claim
implant I-Claim
was I-Claim
the I-Claim
best I-Claim
predictor I-Claim
of I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

the B-Claim
addition I-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
paclitaxel I-Claim
improved I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
( I-Claim
pfs I-Claim
) I-Claim
of I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
( I-Claim
mbc I-Claim
) I-Claim
. I-Claim

we O
examined O
the O
efficacy O
and O
safety O
of O
adding O
gemcitabine O
to O
paclitaxel O
/ O
bevacizumab O
( O
pb O
) O
. O

in O
this O
multicenter O
, O
open O
- O
label O
, O
randomized O
phase O
ii O
trial O
, O
women O
with O
locally O
advanced O
or O
mbc O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
90 O
mg O
/ O
m O
( O
2 O
) O
( O
days O
1 O
, O
8 O
, O
15 O
) O
and O
bevacizumab O
10 O
mg O
/ O
kg O
( O
days O
1 O
, O
15 O
) O
with O
or O
without O
gemcitabine O
1500 O
mg O
/ O
m O
( O
2 O
) O
( O
days O
1 O
, O
15 O
) O
in O
28 O
- O
day O
cycles O
. O

patients O
with O
prior O
cytotoxic O
therapy O
for O
mbc O
were O
ineligible O
. O

the O
primary O
endpoint O
was O
investigator O
- O
assessed O
overall O
response O
rate O
( O
orr O
) O
"""" O
; O
"""" O
secondary O
endpoints O
were O
pfs O
, O
overall O
survival O
( O
os O
) O
, O
safety O
, O
and O
quality O
of O
life O
. O

ninety O
- O
four O
patients O
received O
pb O
, O
and O
93 O
received O
paclitaxel O
/ O
bevacizumab O
/ O
gemcitabine O
( O
pb O
+ O
g O
) O
. O

the B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
pb I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
orr I-Claim
. I-Claim

treatment B-Claim
with I-Claim
pb I-Claim
+ I-Claim
g I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

maintenance O
therapy O
, O
commenced O
immediately O
after O
the O
completion O
of O
first O
- O
line O
chemotherapy O
, O
is O
a O
promising O
strategy O
for O
improving O
treatment O
outcomes O
in O
patients O
with O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
. O

the O
global O
phase O
iii O
sequential O
tarceva O
in O
unresectable O
nsclc O
( O
saturn O
) O
study O
evaluated O
the O
efficacy O
and O
safety O
of O
the O
epidermal O
growth O
factor O
receptor O
( O
egfr O
) O
tyrosine O
- O
kinase O
inhibitor O
erlotinib O
as O
maintenance O
treatment O
in O
nsclc O
patients O
without O
progression O
after O
first O
- O
line O
chemotherapy O
. O

we O
report O
a O
retrospective O
subanalysis O
of O
asian O
patients O
enrolled O
in O
saturn O
. O

patients O
with O
advanced O
nsclc O
with O
no O
evidence O
of O
progression O
after O
four O
cycles O
of O
chemotherapy O
were O
randomized O
to O
receive O
erlotinib O
150 O
mg O
/ O
day O
or O
placebo O
, O
until O
progressive O
disease O
or O
limiting O
toxicity O
. O

the O
co O
- O
primary O
endpoints O
of O
saturn O
were O
progression O
- O
free O
survival O
( O
pfs O
) O
in O
all O
patients O
and O
in O
those O
with O
positive O
egfr O
immunohistochemistry O
( O
ihc O
) O
status O
. O

secondary O
endpoints O
included O
overall O
survival O
( O
os O
) O
, O
disease O
control O
rate O
, O
safety O
, O
quality O
of O
life O
( O
qol O
) O
and O
biomarker O
analyses O
. O

in O
total O
, O
126 O
patients O
from O
east O
and O
south O
- O
east O
asian O
centers O
were O
randomized O
( O
14 O
% O
of O
the O
intent O
- O
to O
- O
treat O
population O
) O
: O
88 O
from O
korea O
, O
28 O
from O
china O
and O
10 O
from O
malaysia O
"""" O
; O
"""" O
one O
patient O
was O
excluded O
from O
this O
analysis O
due O
to O
indian O
ethnicity O
. O

erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
qol I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim

erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
saturn I-Claim
population I-Claim
. I-Claim

maintenance B-Claim
treatment I-Claim
with I-Claim
erlotinib I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
asian I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
without I-Claim
progression I-Claim
after I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
. I-Claim

to O
evaluate O
the O
safety O
and O
efficacy O
of O
abatacept O
during O
2 O
years O
of O
the O
attain O
( O
abatacept O
trial O
in O
treatment O
of O
anti O
- O
tnf O
inadequate O
responders O
) O
trial O
in O
patients O
with O
rheumatoid O
arthritis O
. O

patients O
completing O
the O
6 O
- O
month O
, O
double O
- O
blind O
period O
were O
eligible O
to O
enter O
the O
long O
- O
term O
extension O
"""" O
; O
"""" O
patients O
received O
abatacept O
approximately O
10 O
mg O
/ O
kg O
, O
plus O
disease O
- O
modifying O
antirheumatic O
drugs O
. O

safety O
and O
efficacy O
( O
american O
college O
of O
rheumatology O
( O
acr O
) O
criteria O
responses O
, O
das28 O
( O
c O
- O
reactive O
protein O
) O
, O
haq O
- O
di O
, O
sf O
- O
36 O
, O
medical O
outcomes O
study O
sleep O
problems O
index O
, O
fatigue O
vas O
) O
were O
assessed O
through O
2 O
years O
. O

317 O
patients O
( O
218 O
from O
the O
abatacept O
and O
99 O
from O
the O
placebo O
group O
) O
entered O
and O
222 O
( O
70 O
% O
) O
completed O
18 O
months O
of O
long O
- O
term O
extension O
treatment O
. O

gemcitabine O
for O
advanced O
pancreatic O
cancer O
( O
apc O
) O
is O
palliative O
and O
the O
prognosis O
is O
poor O
, O
making O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
particularly O
important O
. O

we O
evaluated O
hrqol O
with O
the O
euroqol O
( O
eq O
- O
5dâ„¢ O
) O
in O
patients O
with O
apc O
participating O
in O
cancer O
and O
leukemia O
group O
b O
80303 O
, O
a O
multicenter O
, O
double O
- O
blind O
, O
randomized O
trial O
comparing O
overall O
survival O
( O
os O
) O
between O
two O
treatment O
arms O
: O
gemcitabine O
with O
bevacizumab O
or O
gemcitabine O
with O
placebo O
. O

a O
consecutive O
subsample O
of O
patients O
was O
invited O
to O
complete O
the O
eq O
- O
5d O
surveys O
. O

because O
neither O
clinical O
nor O
hrqol O
outcomes O
differed O
based O
on O
the O
study O
arm O
, O
analyses O
were O
pooled O
. O

changes O
in O
mean O
scores O
from O
baseline O
to O
eight O
weeks O
and O
the O
prognostic O
value O
of O
the O
eq O
- O
5d O
were O
evaluated O
. O

baseline O
scores O
from O
both O
eq O
- O
5d O
scales O
were O
significant O
predictors O
of O
os O
in O
cox O
proportional O
hazard O
models O
. O

response B-Claim
to I-Claim
gemcitabine I-Claim
treatment I-Claim
in I-Claim
apc I-Claim
is I-Claim
not I-Claim
associated I-Claim
with I-Claim
appreciable I-Claim
improvement I-Claim
of I-Claim
global I-Claim
hrqol I-Claim
. I-Claim

small O
improvements O
in O
pain O
and O
mood O
are O
observed O
despite O
progressive O
functional O
decline O
. O

those B-Claim
who I-Claim
respond I-Claim
to I-Claim
gemcitabine I-Claim
may I-Claim
experience I-Claim
a I-Claim
slight I-Claim
slowing I-Claim
of I-Claim
functional I-Claim
deterioration I-Claim
. I-Claim

bone O
- O
cancer O
pain O
is O
a O
common O
and O
refractory O
cancer O
pain O
. O

opioids O
, O
on O
their O
own O
, O
do O
not O
control O
this O
type O
of O
pain O
well O
enough O
, O
and O
co O
- O
analgesics O
are O
necessary O
. O

patients O
with O
bone O
metastasis O
- O
related O
pain O
at O
numeric O
rating O
scale O
â‰¥4 O
were O
enrolled O
to O
this O
randomized O
placebo O
- O
controlled O
trial O
. O

they O
had O
also O
received O
morphine O
or O
transdermal O
fentanyl O
patches O
for O
at O
least O
1 O
week O
. O

during O
the O
3 O
- O
day O
efficacy O
phase O
, O
patients O
received O
placebo O
or O
1 O
- O
3 O
tablets O
of O
oxycodone O
/ O
paracetamol O
( O
5 O
/ O
325 O
mg O
) O
, O
four O
times O
daily O
for O
3 O
days O
. O

all O
patients O
kept O
a O
daily O
pain O
diary O
. O

the O
primary O
endpoint O
was O
the O
pain O
intensity O
difference O
( O
pid O
) O
. O

secondary O
endpoints O
were O
cases O
of O
breakthrough O
pain O
and O
rescue O
morphine O
consumption O
. O

additional O
analyses O
included O
the O
short O
form O
- O
6 O
dimensions O
( O
sf O
- O
6d O
) O
quality O
- O
of O
- O
life O
scale O
and O
a O
general O
impression O
( O
gi O
) O
of O
patient O
satisfaction O
with O
treatment O
at O
the O
end O
of O
the O
phase O
. O

of O
the O
246 O
patients O
in O
the O
intent O
- O
to O
- O
treat O
set O
, O
89 O
Â· O
4 O
% O
completed O
the O
3 O
- O
day O
efficacy O
phase O
. O

patients B-Claim
with I-Claim
bone I-Claim
- I-Claim
cancer I-Claim
pain I-Claim
, I-Claim
already I-Claim
on I-Claim
opioids I-Claim
, I-Claim
obtain I-Claim
clinically I-Claim
important I-Claim
, I-Claim
additional I-Claim
pain I-Claim
- I-Claim
control I-Claim
, I-Claim
with I-Claim
regular I-Claim
oxycodone I-Claim
/ I-Claim
paracetamol I-Claim
dosing I-Claim
. I-Claim

to O
examine O
the O
effects O
of O
a O
seated O
exercise O
program O
on O
fatigue O
and O
quality O
of O
life O
( O
qol O
) O
in O
women O
with O
metastatic O
breast O
cancer O
. O

randomized O
, O
controlled O
, O
longitudinal O
trial O
. O

outpatient O
clinic O
of O
a O
comprehensive O
cancer O
center O
. O

convenience O
sample O
of O
38 O
women O
who O
were O
beginning O
outpatient O
chemotherapy O
. O

subjects O
were O
randomized O
to O
a O
control O
or O
intervention O
group O
"""" O
; O
"""" O
the O
intervention O
was O
performance O
of O
a O
seated O
exercise O
program O
using O
home O
videotape O
three O
times O
per O
week O
for O
four O
cycles O
of O
chemotherapy O
. O

all O
subjects O
completed O
the O
functional O
assessment O
of O
chronic O
illness O
therapy O
fatigue O
version O
iv O
( O
facit O
f O
) O
at O
baseline O
and O
at O
the O
time O
of O
the O
next O
three O
cycles O
. O

subjects O
were O
asked O
to O
document O
the O
frequency O
, O
duration O
, O
and O
intensity O
of O
all O
exercise O
participation O
on O
monthly O
calendars O
. O

exercise O
, O
fatigue O
, O
and O
qol O
. O

32 O
subjects O
, O
16 O
per O
group O
, O
completed O
the O
study O
follow O
- O
up O
. O

seated B-Claim
exercise I-Claim
may I-Claim
be I-Claim
a I-Claim
feasible I-Claim
exercise I-Claim
program I-Claim
for I-Claim
women I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
for I-Claim
controlling I-Claim
fatigue I-Claim
and I-Claim
improving I-Claim
physical I-Claim
well I-Claim
- I-Claim
being I-Claim
. I-Claim

few O
intervention O
programs O
assist O
patients O
and O
their O
family O
caregivers O
to O
manage O
advanced O
cancer O
and O
maintain O
their O
quality O
of O
life O
( O
qol O
) O
. O

this O
study O
examined O
( O
i O
) O
whether O
patient O
- O
caregiver O
dyads O
( O
i O
. O
e O
. O
, O
pairs O
) O
randomly O
assigned O
to O
a O
brief O
or O
extensive O
dyadic O
intervention O
( O
the O
focus O
program O
) O
had O
better O
outcomes O
than O
dyads O
randomly O
assigned O
to O
usual O
care O
and O
( O
ii O
) O
whether O
patients O
' O
risk O
for O
distress O
and O
other O
factors O
moderated O
the O
effect O
of O
the O
brief O
or O
extensive O
program O
on O
outcomes O
. O

advanced O
cancer O
patients O
and O
their O
caregivers O
( O
n O
= O
484 O
dyads O
) O
were O
stratified O
by O
patients O
' O
baseline O
risk O
for O
distress O
( O
high O
versus O
low O
) O
, O
cancer O
type O
( O
lung O
, O
colorectal O
, O
breast O
, O
or O
prostate O
) O
, O
and O
research O
site O
and O
then O
randomly O
assigned O
to O
a O
brief O
( O
three O
- O
session O
) O
or O
extensive O
( O
six O
- O
session O
) O
intervention O
or O
control O
. O

the O
interventions O
offered O
dyads O
information O
and O
support O
. O

intermediary O
outcomes O
were O
appraisals O
( O
i O
. O
e O
. O
, O
appraisal O
of O
illness O
/ O
caregiving O
, O
uncertainty O
, O
and O
hopelessness O
) O
and O
resources O
( O
i O
. O
e O
. O
, O
coping O
, O
interpersonal O
relationships O
, O
and O
self O
- O
efficacy O
) O
. O

the O
primary O
outcome O
was O
qol O
. O

data O
were O
collected O
prior O
to O
intervention O
and O
post O
- O
intervention O
( O
3 O
and O
6 O
months O
from O
baseline O
) O
. O

the O
final O
sample O
was O
302 O
dyads O
. O

repeated O
measures O
mancova O
was O
used O
to O
evaluate O
outcomes O
. O

effects O
varied O
by O
intervention O
dose O
. O

most O
effects O
were O
found O
at O
3 O
months O
only O
. O

patient B-Claim
- B-Claim
caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
' I-Claim
unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim

to O
observe O
the O
clinical O
efficacy O
of O
shenqi O
fuzheng O
injection O
( O
sfi O
) O
combined O
with O
chemotherapy O
in O
treating O
patients O
with O
advanced O
breast O
cancer O
. O

sixty O
patients O
were O
randomly O
assigned O
to O
two O
groups O
by O
digital O
table O
, O
the O
control O
group O
and O
the O
treatment O
group O
, O
30 O
in O
each O
group O
. O

all O
patients O
were O
treated O
with O
the O
same O
ctf O
regimen O
of O
chemotherapy O
for O
21 O
days O
as O
one O
therapeutic O
cycle O
, O
while O
those O
in O
the O
treatment O
group O
were O
given O
sfi O
additionally O
in O
the O
meanwhite O
. O

the O
therapeutic O
efficacy O
was O
evaluated O
after O
2 O
cycles O
of O
treatment O
by O
observing O
the O
changes O
of O
short O
- O
term O
efficacy O
, O
tcm O
syndrome O
, O
quality O
of O
life O
and O
immune O
function O
, O
as O
well O
as O
the O
adverse O
reaction O
. O

for B-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
sfi I-Claim
can I-Claim
alleviate I-Claim
the I-Claim
bone I-Claim
marrow I-Claim
inhibition I-Claim
caused I-Claim
by I-Claim
chemotherapy I-Claim
, I-Claim
improve I-Claim
clinical I-Claim
symptoms I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
the I-Claim
survival I-Claim
period I-Claim
by I-Claim
regulating I-Claim
cellular I-Claim
immune I-Claim
function I-Claim
of I-Claim
patients I-Claim
, I-Claim
so I-Claim
as I-Claim
to I-Claim
enhance I-Claim
the I-Claim
therapeutic I-Claim
effect I-Claim
of I-Claim
chemotherapy I-Claim
. I-Claim

the O
american O
college O
of O
surgeons O
oncology O
group O
phase O
iii O
surgical O
prostatectomy O
versus O
interstitial O
radiation O
intervention O
trial O
comparing O
radical O
prostatectomy O
( O
rp O
) O
and O
brachytherapy O
( O
bt O
) O
closed O
after O
2 O
years O
due O
to O
poor O
accrual O
. O

we O
report O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
at O
a O
mean O
of O
5 O
. O
3 O
years O
for O
168 O
trial O
- O
eligible O
men O
who O
either O
chose O
or O
were O
randomly O
assigned O
to O
rp O
or O
bt O
following O
a O
multidisciplinary O
educational O
session O
. O

after O
initial O
lack O
of O
accrual O
, O
a O
multidisciplinary O
educational O
session O
was O
introduced O
for O
eligible O
patients O
. O

in O
all O
, O
263 O
men O
attended O
47 O
sessions O
. O

of O
those O
, O
34 O
consented O
to O
random O
assignment O
, O
62 O
chose O
rp O
, O
and O
94 O
chose O
bt O
. O

five O
years O
later O
, O
these O
190 O
men O
underwent O
hrqol O
evaluation O
by O
using O
the O
cancer O
- O
specific O
50 O
- O
item O
expanded O
prostate O
cancer O
index O
composite O
, O
the O
short O
form O
12 O
physical O
component O
score O
, O
and O
short O
form O
12 O
mental O
component O
score O
. O

response O
rate O
was O
88 O
. O
4 O
% O
. O

the O
wilcoxon O
rank O
sum O
test O
was O
used O
to O
compare O
summary O
scores O
between O
the O
two O
interventions O
. O

of O
168 O
survey O
responders O
, O
60 O
. O
7 O
% O
had O
bt O
( O
9 O
. O
5 O
% O
randomly O
assigned O
) O
and O
39 O
. O
3 O
% O
had O
rp O
( O
9 O
. O
5 O
% O
randomly O
assigned O
) O
. O

median O
age O
was O
61 O
. O
4 O
years O
for O
bt O
and O
59 O
. O
4 O
for O
rp O
( O
p O
= O
. O
05 O
) O
. O

median O
follow O
- O
up O
was O
5 O
. O
2 O
years O
( O
range O
, O
3 O
. O
2 O
to O
6 O
. O
5 O
years O
) O
. O

although O
treatment O
allocation O
was O
random O
in O
only O
19 O
% O
, O
all O
patients O
received O
identical O
information O
in O
a O
multidisciplinary O
setting O
before O
selecting O
rp O
, O
bt O
, O
or O
random O
assignment O
. O

hrqol B-Claim
evaluated I-Claim
3 I-Claim
. I-Claim
2 I-Claim
to I-Claim
6 I-Claim
. I-Claim
5 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
showed I-Claim
an I-Claim
advantage I-Claim
for I-Claim
bt I-Claim
in I-Claim
urinary I-Claim
and I-Claim
sexual I-Claim
domains I-Claim
and I-Claim
in I-Claim
patient I-Claim
satisfaction I-Claim
. I-Claim

a O
multidimensional O
rehabilitation O
program O
for O
cancer O
survivors O
was O
developed O
to O
overcome O
cancer O
- O
related O
problems O
and O
to O
improve O
quality O
of O
life O
. O

the O
two O
purposes O
of O
the O
study O
were O
to O
describe O
the O
effectiveness O
of O
the O
program O
and O
to O
obtain O
information O
about O
patient O
preferences O
for O
multi O
or O
mono O
dimensional O
rehabilitation O
programs O
. O

cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer O
- O
related O
physical O
and O
psychosocial O
problems O
. O

a O
15 O
- O
week O
rehabilitation O
program O
including O
individual O
exercise O
, O
sports O
, O
psycho O
- O
education O
, O
and O
information O
. O

group O
- O
wise O
randomization O
was O
implemented O
by O
assigning O
one O
half O
of O
the O
patients O
to O
the O
complete O
program O
while O
the O
other O
half O
were O
allowed O
to O
choose O
which O
program O
components O
they O
considered O
relevant O
. O

health O
- O
related O
quality O
of O
life O
[ O
rand O
- O
36 O
and O
rotterdam O
symptom O
check O
list O
( O
rscl O
) O
] O
, O
exercise O
capacity O
( O
symptom O
limited O
bicycle O
ergometry O
) O
, O
muscle O
force O
( O
hand O
- O
held O
dynamometry O
) O
, O
and O
patient O
preferences O
. O

measurements O
were O
performed O
before O
( O
t0 O
) O
and O
after O
the O
rehabilitation O
program O
( O
t1 O
) O
, O
and O
at O
a O
3 O
- O
month O
follow O
- O
up O
( O
t2 O
) O
. O

a B-Claim
multidimensional I-Claim
rehabilitation I-Claim
program I-Claim
has I-Claim
statistically I-Claim
and I-Claim
clinically I-Claim
relevant I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
exercise I-Claim
capacity I-Claim
, I-Claim
and I-Claim
muscle I-Claim
force I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
different I-Claim
diagnoses I-Claim
. I-Claim

furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim

surgery O
and O
radiotherapy O
commonly O
cause O
adverse O
musculoskeletal O
problems O
, O
particularly O
loss O
of O
strength O
and O
range O
of O
motion O
, O
in O
the O
upper O
quadrant O
of O
breast O
cancer O
patients O
. O

few O
well O
- O
designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O

stretching B-Claim
is I-Claim
an I-Claim
effective I-Claim
technique I-Claim
for I-Claim
increasing I-Claim
range I-Claim
of I-Claim
motion I-Claim
, I-Claim
hence O
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
a O
stretching O
program O
reduced O
acute O
musculoskeletal O
impairments O
in O
patients O
undergoing O
radiotherapy O
for O
breast O
cancer O
. O

sixty O
- O
four O
women O
were O
recruited O
prior O
to O
commencement O
of O
radiotherapy O
following O
breast O
cancer O
surgery O
. O

participants O
were O
randomised O
to O
either O
a O
control O
or O
stretch O
group O
. O

participants O
in O
both O
groups O
were O
reviewed O
by O
the O
physical O
therapist O
on O
a O
weekly O
basis O
for O
approximately O
6 O
weeks O
, O
and O
were O
given O
general O
information O
about O
skin O
care O
and O
lymphedema O
. O

the O
control O
group O
received O
no O
advice O
about O
exercise O
. O

the O
stretch O
group O
received O
instruction O
on O
low O
- O
load O
, O
prolonged O
pectoral O
stretches O
, O
which O
were O
to O
be O
performed O
daily O
and O
were O
checked O
at O
weekly O
visits O
. O

shoulder O
range O
of O
motion O
, O
strength O
, O
arm O
circumference O
, O
and O
quality O
of O
life O
measurements O
were O
taken O
prior O
to O
, O
and O
at O
completion O
of O
radiotherapy O
, O
and O
at O
7 O
months O
after O
radiotherapy O
. O

postoperative B-Claim
outcomes I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
laparoscopic I-Claim
- I-Claim
assisted I-Claim
colectomy I-Claim
( I-Claim
lac I-Claim
) I-Claim
have I-Claim
shown I-Claim
modest I-Claim
improvements I-Claim
in I-Claim
recovery I-Claim
but I-Claim
only I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
compared I-Claim
with I-Claim
open I-Claim
colectomy I-Claim
. I-Claim

we O
therefore O
sought O
to O
assess O
the O
effect O
of O
lac O
on O
qol O
in O
the O
short O
and O
long O
term O
, O
using O
individual O
item O
analysis O
of O
multi O
- O
item O
qol O
assessments O
. O

qol O
variables O
were O
analyzed O
in O
449 O
randomized O
patients O
from O
the O
cost O
trial O
93 O
- O
46 O
- O
53 O
( O
int O
146 O
) O
. O

both O
cross O
- O
sectional O
single O
- O
time O
and O
change O
from O
baseline O
assessments O
were O
run O
at O
day O
2 O
, O
week O
2 O
, O
month O
2 O
, O
and O
month O
18 O
postoperatively O
in O
an O
intention O
- O
to O
- O
treat O
analysis O
using O
wilcoxon O
rank O
- O
sum O
tests O
. O

stepwise O
regression O
models O
were O
used O
to O
determine O
predictors O
of O
qol O
. O

of O
449 O
colon O
cancer O
patients O
, O
230 O
underwent O
lac O
and O
219 O
underwent O
open O
colectomy O
. O

poor O
preoperative O
qol O
as O
indicated O
by O
a O
rating O
scale O
of O
â‰¤ O
50 O
was O
an O
independent O
predictor O
of O
poor O
qol O
at O
2 O
months O
postoperatively O
. O

qol O
variables O
related O
to O
survival O
were O
baseline O
support O
( O
p O
= O
0 O
. O
001 O
) O
and O
baseline O
outlook O
( O
p O
= O
0 O
. O
01 O
) O
. O

patients B-Claim
with I-Claim
poor I-Claim
preoperative I-Claim
qol I-Claim
appear I-Claim
to I-Claim
be I-Claim
at I-Claim
higher I-Claim
risk I-Claim
for I-Claim
difficult I-Claim
postoperative I-Claim
courses I-Claim
, I-Claim
and I-Claim
may I-Claim
be I-Claim
candidates I-Claim
for I-Claim
enhanced I-Claim
ancillary I-Claim
services I-Claim
to I-Claim
address I-Claim
their I-Claim
particular I-Claim
needs I-Claim
. I-Claim

the O
goal O
of O
this O
study O
was O
to O
assess O
the O
impact O
of O
neuronavigation O
on O
the O
cytoreductive O
treatment O
of O
solitary O
contrast O
- O
enhancing O
intracerebral O
tumors O
and O
outcomes O
of O
this O
treatment O
in O
cases O
in O
which O
neuronavigation O
was O
preoperatively O
judged O
to O
be O
redundant O
. O

the O
authors O
conducted O
a O
prospective O
randomized O
study O
in O
which O
45 O
patients O
, O
each O
harboring O
a O
solitary O
contrast O
- O
enhancing O
intracerebral O
tumor O
, O
were O
randomized O
for O
surgery O
with O
or O
without O
neuronavigation O
. O

peri O
- O
and O
postoperative O
parameters O
under O
investigation O
included O
the O
following O
: O
duration O
of O
the O
procedure O
"""" O
; O
"""" O
surgeon O
' O
s O
estimate O
of O
the O
usefulness O
of O
neuronavigation O
"""" O
; O
"""" O
quantification O
of O
the O
extent O
of O
resection O
, O
determined O
using O
magnetic O
resonance O
imaging O
"""" O
; O
"""" O
and O
the O
postoperative O
course O
, O
as O
evaluated O
by O
neurological O
examinations O
, O
the O
patient O
' O
s O
quality O
- O
of O
- O
life O
self O
- O
assessment O
, O
application O
of O
the O
barthel O
index O
and O
the O
karnofsky O
performance O
scale O
score O
, O
and O
the O
patient O
' O
s O
time O
of O
death O
. O

there B-Claim
is I-Claim
no I-Claim
rationale I-Claim
for I-Claim
the I-Claim
routine I-Claim
use I-Claim
of I-Claim
neuronavigation I-Claim
to I-Claim
improve I-Claim
the I-Claim
extent I-Claim
of I-Claim
tumor I-Claim
resection I-Claim
and I-Claim
prognosis I-Claim
in I-Claim
patients I-Claim
harboring I-Claim
a I-Claim
solitary I-Claim
enhancing I-Claim
intracerebral I-Claim
lesion I-Claim
when I-Claim
neuronavigation I-Claim
is I-Claim
not I-Claim
already I-Claim
deemed I-Claim
advantageous I-Claim
because I-Claim
of I-Claim
the I-Claim
size I-Claim
or I-Claim
location I-Claim
of I-Claim
the I-Claim
lesion I-Claim
. I-Claim

to O
test O
the O
ability O
of O
the O
cytoprotectant O
, O
amifostine O
, O
to O
reduce O
chemoradiotherapy O
- O
induced O
esophagitis O
and O
evaluate O
its O
influence O
on O
quality O
of O
life O
( O
qol O
) O
and O
swallowing O
symptoms O
. O

a O
total O
of O
243 O
patients O
with O
stage O
ii O
to O
iiia O
/ O
b O
non O
- O
small O
- O
cell O
lung O
cancer O
received O
induction O
paclitaxel O
225 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
( O
iv O
) O
days O
1 O
and O
22 O
and O
carboplatin O
area O
under O
the O
curve O
( O
auc O
) O
days O
1 O
and O
22 O
, O
followed O
by O
concurrent O
weekly O
paclitaxel O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
iv O
) O
and O
carboplatin O
( O
auc O
2 O
) O
, O
and O
hyperfractionated O
radiation O
therapy O
( O
69 O
. O
6 O
gy O
at O
1 O
. O
2 O
gy O
bid O
) O
. O

patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
am O
) O
500 O
mg O
iv O
four O
times O
per O
week O
or O
no O
am O
during O
chemoradiotherapy O
. O

beyond O
standard O
toxicity O
end O
points O
, O
physician O
dysphagia O
logs O
( O
pdls O
) O
, O
daily O
patient O
swallowing O
diaries O
, O
and O
qol O
( O
eortc O
qlq O
- O
c30 O
/ O
lc O
- O
13 O
) O
were O
also O
collected O
. O

swallowing O
auc O
analyses O
were O
calculated O
from O
patient O
diaries O
and O
pdls O
. O

a O
total O
of O
120 O
patients O
were O
randomly O
assigned O
to O
receive O
am O
, O
and O
122 O
, O
to O
receive O
no O
am O
( O
one O
patient O
was O
ineligible O
) O
"""" O
; O
"""" O
72 O
% O
received O
am O
per O
protocol O
or O
with O
a O
minor O
deviation O
. O

am B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/ I-Claim
= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim

however B-Claim
, I-Claim
patient I-Claim
self I-Claim
- I-Claim
assessments I-Claim
suggested I-Claim
a I-Claim
possible I-Claim
advantage I-Claim
to I-Claim
am I-Claim
that I-Claim
is I-Claim
being I-Claim
explored I-Claim
with I-Claim
modified I-Claim
dosing I-Claim
route I-Claim
strategies I-Claim
. I-Claim

the O
impact O
of O
the O
side O
effects O
of O
megestrol O
acetate O
on O
the O
quality O
of O
life O
of O
noncachectic O
women O
with O
advanced O
breast O
cancer O
was O
studied O
in O
a O
dose O
- O
response O
clinical O
trial O
of O
the O
cancer O
and O
leukemia O
group O
b O
( O
calgb O
8741 O
) O
. O

side O
effects O
of O
appetite O
increase O
and O
weight O
gain O
at O
higher O
doses O
were O
predicted O
to O
have O
a O
negative O
effect O
on O
quality O
of O
life O
. O

stage O
iv O
breast O
cancer O
patients O
were O
randomized O
to O
receive O
either O
160 O
, O
800 O
, O
or O
1 O
, O
600 O
mg O
/ O
d O
of O
megestrol O
acetate O
. O

quality O
of O
life O
was O
assessed O
in O
131 O
patients O
at O
trial O
entry O
and O
at O
1 O
and O
3 O
months O
while O
on O
treatment O
, O
by O
telephone O
interview O
, O
using O
the O
following O
measures O
: O
the O
functional O
living O
index O
- O
cancer O
( O
flic O
) O
, O
rand O
functional O
limitations O
scale O
, O
rand O
mental O
health O
inventory O
( O
mhi O
) O
, O
the O
body O
image O
subscale O
, O
and O
linear O
analog O
scales O
of O
drug O
side O
effects O
. O

patients B-Premise
who I-Premise
received I-Premise
the I-Premise
800 I-Premise
- I-Premise
mg I-Premise
/ I-Premise
d I-Premise
dose I-Premise
fell I-Premise
between I-Premise
the I-Premise
low I-Premise
- I-Premise
and I-Premise
high I-Premise
- I-Premise
dose I-Premise
arms I-Premise
in I-Premise
reported I-Premise
intensity I-Premise
of I-Premise
drug I-Premise
side I-Premise
effects I-Premise
, I-Premise
but B-Premise
responded I-Premise
similarly I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
160 I-Premise
- I-Premise
mg I-Premise
/ I-Premise
d I-Premise
group I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
psychologic I-Premise
distress I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

unless B-Claim
additional I-Claim
follow I-Claim
- I-Claim
up I-Claim
data I-Claim
demonstrate I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
at I-Claim
higher I-Claim
doses I-Claim
, I-Claim
the I-Claim
160 I-Claim
- I-Claim
mg I-Claim
/ I-Claim
d I-Claim
dose I-Claim
is I-Claim
optimal I-Claim
, I-Claim
achieving I-Claim
maximal I-Claim
treatment I-Claim
effect I-Claim
with I-Claim
the I-Claim
fewest I-Claim
side I-Claim
effects I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

study O
type O
- O
- O
therapy O
( O
rct O
) O
level O
of O
evidence O
1b O
. O

what O
' O
s O
known O
on O
the O
subject O
? O

and O
what O
does O
the O
study O
add O
? O

androgen O
deprivation O
therapy O
( O
adt O
) O
is O
commonly O
used O
as O
a O
primary O
treatment O
for O
patients O
with O
prostate O
cancer O
( O
pca O
) O
who O
are O
not O
eligible O
for O
radical O
treatment O
options O
. O

adt O
is O
also O
used O
in O
patients O
with O
pca O
as O
neo O
- O
adjuvant O
hormone O
therapy O
to O
reduce O
prostate O
volume O
and O
down O
- O
stage O
the O
disease O
before O
radiotherapy O
with O
curative O
intent O
. O

the O
present O
study O
showed O
that O
adt O
with O
the O
gonadotropin O
hormone O
- O
releasing O
hormone O
( O
ghrh O
) O
antagonist O
degarelix O
is O
non O
- O
inferior O
to O
combined O
treatment O
with O
the O
lhrh O
agonist O
goserelin O
and O
bicalutamide O
in O
terms O
of O
reducing O
prostate O
volume O
during O
the O
treatment O
period O
of O
3 O
months O
. O

degarelix O
treatment O
evokes O
, O
however O
, O
significantly O
better O
relief O
of O
lower O
urinary O
tract O
symptoms O
in O
patients O
having O
moderate O
and O
severe O
voiding O
problems O
. O

to O
assess O
the O
efficacy O
of O
monthly O
degarelix O
treatment O
for O
reduction O
of O
total O
prostate O
volume O
( O
tpv O
) O
, O
relief O
of O
lower O
urinary O
tract O
symptoms O
( O
luts O
) O
and O
improvement O
of O
quality O
of O
life O
( O
qol O
) O
in O
patients O
with O
prostate O
cancer O
( O
pca O
) O
using O
monthly O
goserelin O
as O
active O
control O
. O

this O
was O
a O
randomized O
, O
parallel O
- O
arm O
, O
active O
- O
controlled O
, O
open O
- O
label O
, O
multicentre O
trial O
on O
182 O
patients O
treated O
with O
either O
monthly O
degarelix O
( O
240 O
/ O
80 O
mg O
) O
or O
goserelin O
( O
3 O
. O
6 O
mg O
) O
for O
12 O
weeks O
. O

for O
flare O
protection O
, O
goserelin O
- O
treated O
patients O
also O
received O
daily O
bicalutamide O
( O
50 O
mg O
) O
during O
the O
initial O
28 O
days O
. O

key O
trial O
variables O
monitored O
monthly O
were O
tpv O
( O
primary O
endpoint O
) O
, O
serum O
testosterone O
, O
prostate O
- O
specific O
antigen O
( O
psa O
) O
, O
the O
international O
prostate O
symptom O
score O
( O
ipss O
) O
and O
the O
benign O
prostate O
hyperplasia O
impact O
index O
. O

in O
all O
, O
175 O
patients O
completed O
the O
trial O
( O
96 O
. O
1 O
% O
) O
. O

at B-Premise
week I-Premise
12 I-Premise
, I-Premise
changes I-Premise
in I-Premise
tpv I-Premise
for I-Premise
degarelix I-Premise
and I-Premise
goserelin I-Premise
were I-Premise
similar I-Premise
( I-Premise
- I-Premise
37 I-Premise
. I-Premise
2 I-Premise
% I-Premise
vs I-Premise
- I-Premise
39 I-Premise
. I-Premise
0 I-Premise
% I-Premise
) I-Premise
and I-Premise
met I-Premise
the I-Premise
predefined I-Premise
non I-Premise
- I-Premise
inferiority I-Premise
criterion I-Premise
. I-Premise

decreases B-Premise
in I-Premise
ipss I-Premise
were I-Premise
greater I-Premise
in I-Premise
degarelix I-Premise
than I-Premise
in I-Premise
goserelin I-Premise
- I-Premise
treated I-Premise
patients I-Premise
, I-Premise
differences I-Premise
being I-Premise
statistically I-Premise
significant I-Premise
in I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
ipss I-Premise
> I-Premise
13 I-Premise
( I-Premise
- I-Premise
6 I-Premise
. I-Premise
7 I-Premise
Â± I-Premise
1 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
- I-Premise
4 I-Premise
. I-Premise
0 I-Premise
Â± I-Premise
1 I-Premise
. I-Premise
0 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

the B-Premise
number I-Premise
of I-Premise
patients I-Premise
with I-Premise
an I-Premise
ipss I-Premise
change I-Premise
of I-Premise
â‰¥ I-Premise
3 I-Premise
over I-Premise
baseline I-Premise
was I-Premise
also I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
degarelix I-Premise
( I-Premise
61 I-Premise
. I-Premise
0 I-Premise
vs I-Premise
44 I-Premise
. I-Premise
3 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

both B-Claim
treatments I-Claim
were I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

medical B-Claim
castration I-Claim
reduces I-Claim
tpv I-Claim
and I-Claim
could I-Claim
also I-Claim
improve I-Claim
luts I-Claim
in I-Claim
patients I-Claim
with I-Claim
pca I-Claim
. I-Claim

while O
the B-Claim
short I-Claim
- I-Claim
term I-Claim
efficacy I-Claim
of I-Claim
degarelix I-Claim
and I-Claim
goserelin I-Claim
+ I-Claim
bicalutamide I-Claim
was I-Claim
the I-Claim
same I-Claim
in I-Claim
terms I-Claim
of I-Claim
tpv I-Claim
reduction I-Claim
, I-Claim
degarelix B-Claim
showed I-Claim
superiority I-Claim
in I-Claim
luts I-Claim
relief I-Claim
in I-Claim
symptomatic I-Claim
patients I-Claim
, I-Claim
which I-Claim
could I-Claim
highlight I-Claim
the I-Claim
different I-Claim
actions I-Claim
of I-Claim
these I-Claim
drugs I-Claim
on I-Claim
extrapituitary I-Claim
gonadotrophin I-Claim
- I-Claim
releasing I-Claim
hormone I-Claim
( I-Claim
gnrh I-Claim
) I-Claim
receptors I-Claim
in I-Claim
the I-Claim
bladder I-Claim
and I-Claim
/ I-Claim
or I-Claim
the I-Claim
prostate I-Claim
. I-Claim

to O
assess O
whether O
omission O
of O
postoperative O
radiotherapy O
in O
women O
with O
' O
low O
- O
risk O
' O
axillary O
node O
negative O
breast O
cancer O
( O
t0 O
- O
2 O
) O
treated O
by O
breast O
- O
conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost O
- O
effective O
. O

a O
randomised O
controlled O
clinical O
trial O
, O
using O
a O
method O
of O
minimisation O
balanced O
by O
centre O
, O
grade O
of O
cancer O
, O
age O
, O
lymphatic O
/ O
vascular O
invasion O
and O
preoperative O
endocrine O
therapy O
, O
was O
performed O
. O

a O
non O
- O
randomised O
cohort O
was O
also O
recruited O
, O
in O
order O
to O
complete O
a O
comprehensive O
cohort O
study O
. O

the O
setting O
was O
breast O
cancer O
clinics O
in O
cancer O
centres O
in O
the O
uk O
. O

patients O
aged O
65 O
years O
or O
more O
were O
eligible O
provided O
that O
their O
cancers O
were O
considered O
to O
be O
at O
low O
risk O
of O
local O
recurrence O
, O
were O
suitable O
for O
breast O
- O
conservation O
surgery O
, O
were O
receiving O
endocrine O
therapy O
and O
were O
able O
and O
willing O
to O
give O
informed O
consent O
. O

the O
standard O
treatment O
of O
postoperative O
breast O
irradiation O
or O
the O
omission O
of O
radiotherapy O
. O

quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost O
- O
effectiveness O
. O

secondary O
outcome O
measures O
were O
recurrence O
rates O
, O
functional O
status O
, O
treatment O
- O
related O
morbidity O
and O
cosmesis O
. O

the O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
at O
four O
times O
over O
15 O
months O
. O

the B-Claim
hypothesised I-Claim
improvement I-Claim
in I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
with I-Claim
the I-Claim
omission I-Claim
of I-Claim
radiotherapy I-Claim
was I-Claim
not I-Claim
seen I-Claim
in I-Claim
the I-Claim
euroqol I-Claim
assessment I-Claim
or I-Claim
in I-Claim
the I-Claim
functionality I-Claim
and I-Claim
symptoms I-Claim
summary I-Claim
domains I-Claim
of I-Claim
the I-Claim
european I-Claim
organisation I-Claim
for I-Claim
research I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
cancer I-Claim
( I-Claim
eortc I-Claim
) I-Claim
scales I-Claim
. I-Claim

some O
differences O
were O
apparent O
within O
subscales O
of O
the O
eortc O
questionnaires O
, O
and O
insights O
into O
the O
impact O
of O
treatment O
were O
also O
provided O
by O
the O
qualitative O
data O
obtained O
by O
open O
- O
ended O
questions O
. O

differences B-Premise
were I-Premise
most I-Premise
apparent I-Premise
shortly I-Premise
after I-Premise
the I-Premise
time I-Premise
of I-Premise
completion I-Premise
of I-Premise
radiotherapy I-Premise
. I-Premise

radiotherapy B-Claim
was I-Claim
then I-Claim
associated I-Claim
with I-Claim
increased I-Claim
breast I-Claim
symptoms I-Claim
and I-Claim
with I-Claim
greater I-Claim
fatigue I-Claim
but I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
endocrine I-Claim
side I-Claim
- I-Claim
effects I-Claim
. I-Claim

patients B-Premise
had I-Premise
significant I-Premise
concerns I-Premise
about I-Premise
the I-Premise
delivery I-Premise
of I-Premise
radiotherapy I-Premise
services I-Premise
, I-Premise
such I-Premise
as I-Premise
transport I-Premise
, I-Premise
accommodation I-Premise
and I-Premise
travel I-Premise
costs I-Premise
associated I-Premise
with I-Premise
receiving I-Premise
radiotherapy I-Premise
. I-Premise

by B-Premise
the I-Premise
end I-Premise
of I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
radiotherapy I-Premise
were I-Premise
expressing I-Premise
less I-Premise
anxiety I-Premise
about I-Premise
recurrence I-Premise
than I-Premise
those I-Premise
who I-Premise
had I-Premise
not I-Premise
received I-Premise
radiotherapy I-Premise
. I-Premise

functionality B-Premise
was I-Premise
not I-Premise
greatly I-Premise
affected I-Premise
by I-Premise
treatment I-Premise
. I-Premise

within B-Premise
the I-Premise
randomised I-Premise
controlled I-Premise
trial I-Premise
, I-Premise
the I-Premise
barthel I-Premise
index I-Premise
demonstrated I-Premise
a I-Premise
small I-Premise
but I-Premise
significant I-Premise
fall I-Premise
in I-Premise
functionality I-Premise
with I-Premise
radiotherapy I-Premise
compared I-Premise
with I-Premise
the I-Premise
no I-Premise
radiotherapy I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
. I-Premise

results B-Premise
from I-Premise
the I-Premise
non I-Premise
- I-Premise
randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise

cosmetic B-Premise
results I-Premise
were I-Premise
better I-Premise
in I-Premise
those I-Premise
not I-Premise
receiving I-Premise
radiotherapy I-Premise
but B-Premise
this I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
be I-Premise
an I-Premise
important I-Premise
issue I-Premise
to I-Premise
the I-Premise
patients I-Premise
. I-Premise

the B-Claim
use I-Claim
of I-Claim
home I-Claim
- I-Claim
based I-Claim
assessments I-Claim
by I-Claim
a I-Claim
research I-Claim
nurse I-Claim
proved I-Claim
to I-Claim
be I-Claim
an I-Claim
effective I-Claim
way I-Claim
of I-Claim
obtaining I-Claim
high I-Claim
- I-Claim
quality I-Claim
data I-Claim
. I-Claim

costs O
to O
the O
nhs O
associated O
with O
postoperative O
radiotherapy O
were O
calculated O
to O
be O
of O
the O
order O
of O
2000 O
pounds O
per O
patient O
. O

in B-Premise
the I-Premise
follow I-Premise
- I-Premise
up I-Premise
in I-Premise
this I-Premise
study I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
recurrences I-Premise
, I-Premise
and I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
utilities I-Premise
from I-Premise
euroqol I-Premise
were I-Premise
almost I-Premise
identical I-Premise
. I-Premise

although B-Premise
there I-Premise
are I-Premise
no I-Premise
differences I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
the I-Premise
patients I-Premise
treated I-Premise
with I-Premise
and I-Premise
without I-Premise
radiotherapy I-Premise
, I-Premise
there I-Premise
are I-Premise
several I-Premise
dimensions I-Premise
that I-Premise
exhibit I-Premise
significant I-Premise
advantage I-Premise
to I-Premise
the I-Premise
omission I-Premise
of I-Premise
irradiation I-Premise
. I-Premise

over B-Premise
the I-Premise
first I-Premise
15 I-Premise
months I-Premise
, I-Premise
radiotherapy I-Premise
for I-Premise
this I-Premise
population I-Premise
is I-Premise
not I-Premise
a I-Premise
cost I-Premise
- I-Premise
effective I-Premise
treatment I-Premise
. I-Premise

however O
, O
the O
early B-Claim
postoperative I-Claim
outcome I-Claim
does I-Claim
not I-Claim
give I-Claim
a I-Claim
complete I-Claim
answer I-Claim
and O
the B-Claim
eventual I-Claim
cost I-Claim
- I-Claim
effectiveness I-Claim
will I-Claim
only I-Claim
become I-Claim
clear I-Claim
after I-Claim
long I-Claim
- I-Claim
term I-Claim
follow I-Claim
- I-Claim
up I-Claim
. I-Claim

extrapolations B-Claim
from I-Claim
these I-Claim
data I-Claim
suggest I-Claim
that I-Claim
radiotherapy I-Claim
may I-Claim
not I-Claim
be I-Claim
a I-Claim
cost I-Claim
- I-Claim
effective I-Claim
treatment I-Claim
unless I-Claim
it I-Claim
results I-Claim
in I-Claim
a I-Claim
recurrence I-Claim
rate I-Claim
that I-Claim
is I-Claim
at I-Claim
least I-Claim
5 I-Claim
% I-Claim
lower I-Claim
in I-Claim
absolute I-Claim
terms I-Claim
than I-Claim
those I-Claim
treated I-Claim
without I-Claim
radiotherapy I-Claim
. I-Claim

further B-Claim
research I-Claim
is I-Claim
needed I-Claim
into I-Claim
a I-Claim
number I-Claim
of I-Claim
areas I-Claim
including I-Claim
the I-Claim
long I-Claim
- I-Claim
term I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
clinical I-Claim
outcomes I-Claim
, I-Claim
costs I-Claim
and I-Claim
consequences I-Claim
of I-Claim
omitting I-Claim
radiotherapy I-Claim
. I-Claim

a O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
outcome O
of O
early O
oral O
postoperative O
feeding O
( O
eof O
) O
compared O
with O
traditional O
oral O
feeding O
( O
tof O
) O
in O
gynecologic O
oncology O
patients O
undergoing O
a O
complex O
laparotomy O
, O
including O
upper O
abdominal O
surgery O
. O

patients O
aged O
18 O
- O
75 O
years O
, O
undergoing O
an O
elective O
laparotomy O
and O
with O
a O
preoperative O
suspicion O
of O
gynecologic O
malignancy O
, O
were O
eligible O
. O

exclusion O
criteria O
included O
infectious O
conditions O
, O
intestinal O
obstruction O
, O
severe O
malnutrition O
, O
american O
society O
of O
anesthesiologists O
score O
c4 O
, O
intestinal O
resection O
, O
and O
postoperative O
stay O
in O
the O
intensive O
care O
unit O
lasting O
24 O
h O
. O
patients O
allocated O
to O
eof O
received O
liquid O
diet O
in O
the O
first O
postoperative O
day O
and O
then O
regular O
diet O
. O

patients O
received O
traditional O
feeding O
scheme O
until O
resolution O
of O
postoperative O
ileus O
to O
start O
liquid O
diet O
. O

the O
primary O
end O
- O
point O
of O
the O
trial O
was O
length O
of O
hospital O
stay O
. O

between O
january O
1 O
, O
2007 O
, O
and O
november O
17 O
, O
2007 O
, O
a O
total O
of O
143 O
patients O
were O
randomized O
to O
receive O
either O
eof O
or O
tof O
. O

hospital B-Premise
stay I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
eof I-Premise
( I-Premise
n I-Premise
= I-Premise
71 I-Premise
) I-Premise
was I-Premise
4 I-Premise
. I-Premise
7 I-Premise
vs I-Premise
. I-Premise
5 I-Premise
. I-Premise
8 I-Premise
days I-Premise
for I-Premise
the I-Premise
tof I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
72 I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise

the B-Premise
mean I-Premise
level I-Premise
of I-Premise
postoperative I-Premise
satisfaction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
eof I-Premise
group I-Premise
( I-Premise
82 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
. I-Premise
71 I-Premise
. I-Premise
7 I-Premise
mm I-Premise
, I-Premise
p I-Premise
b I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

patients B-Premise
who I-Premise
received I-Premise
the I-Premise
tof I-Premise
scheme I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
overall I-Premise
postoperative I-Premise
complications I-Premise
( I-Premise
39 I-Premise
vs I-Premise
. I-Premise
17 I-Premise
% I-Premise
in I-Premise
eof I-Premise
group I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
and I-Premise
infective I-Premise
complications I-Premise
( I-Premise
14 I-Premise
% I-Premise
in I-Premise
tof I-Premise
group I-Premise
vs I-Premise
. I-Premise
3 I-Premise
% I-Premise
in I-Premise
eof I-Premise
group I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
017 I-Premise
) I-Premise
. I-Premise

variables B-Premise
such I-Premise
as I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
analgesic I-Premise
and I-Premise
antiemetic I-Premise
requirement I-Premise
as I-Premise
well I-Premise
as I-Premise
level I-Premise
of I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
not I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

on B-Claim
the I-Claim
basis I-Claim
of I-Claim
these I-Claim
findings I-Claim
, I-Claim
the I-Claim
policy I-Claim
of I-Claim
eof I-Claim
should I-Claim
be I-Claim
used I-Claim
after I-Claim
a I-Claim
complex I-Claim
gynecologic I-Claim
oncologic I-Claim
laparotomy I-Claim
. I-Claim

insomnia B-Claim
is I-Claim
a I-Claim
common I-Claim
complaint I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

fortunately O
, O
cognitive O
- O
behavioral O
therapy O
for O
insomnia O
( O
cbt O
- O
i O
) O
has O
been O
shown O
to O
be O
an O
effective O
treatment O
in O
this O
population O
. O

however O
, O
it O
is O
rarely O
implemented O
given O
its O
limited O
availability O
. O

to O
address O
this O
barrier O
, O
we O
examined O
the O
ability O
of O
an O
easily O
accessible O
online O
cbt O
- O
i O
program O
to O
improve O
insomnia O
symptoms O
in O
cancer O
survivors O
. O

twenty O
- O
eight O
cancer O
survivors O
with O
insomnia O
were O
randomly O
assigned O
to O
either O
an O
internet O
insomnia O
intervention O
( O
n O
= O
14 O
) O
or O
to O
a O
waitlist O
control O
group O
( O
n O
= O
14 O
) O
. O

the O
online O
program O
, O
sleep O
healthy O
using O
the O
internet O
, O
delivers O
the O
primary O
components O
of O
cbt O
- O
i O
( O
sleep O
restriction O
, O
stimulus O
control O
, O
cognitive O
restructuring O
, O
sleep O
hygiene O
, O
and O
relapse O
prevention O
) O
. O

pre O
- O
and O
post O
- O
assessment O
data O
were O
collected O
via O
online O
questionnaires O
and O
daily O
sleep O
diaries O
. O

participants B-Premise
in I-Premise
the I-Premise
internet I-Premise
group I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
at I-Premise
post I-Premise
- I-Premise
assessment I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
in I-Premise
overall I-Premise
insomnia I-Premise
severity I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
26 I-Premise
) I-Premise
= I-Premise
22 I-Premise
. I-Premise
8 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
efficiency I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
11 I-Premise
. I-Premise
45 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
onset I-Premise
latency I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
5 I-Premise
. I-Premise
18 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
soundness I-Premise
of I-Premise
sleep I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
9 I-Premise
. I-Premise
34 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
, I-Premise
restored I-Premise
feeling I-Premise
upon I-Premise
awakening I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
11 I-Premise
. I-Premise
95 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
and I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
26 I-Premise
) I-Premise
= I-Premise
13 I-Premise
. I-Premise
88 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

although B-Premise
other I-Premise
group I-Premise
Ã— I-Premise
time I-Premise
interactions I-Premise
were I-Premise
not I-Premise
significant I-Premise
, I-Premise
overall I-Premise
adjusted I-Premise
effect I-Premise
sizes I-Premise
for I-Premise
all I-Premise
sleep I-Premise
variables I-Premise
as I-Premise
well I-Premise
as I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
depression I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
ranged I-Premise
from I-Premise
small I-Premise
to I-Premise
large I-Premise
. I-Premise

cbt B-Claim
- B-Claim
i B-Claim
delivered I-Claim
through I-Claim
an I-Claim
interactive I-Claim
, I-Claim
individually I-Claim
tailored I-Claim
internet I-Claim
intervention I-Claim
may I-Claim
be I-Claim
a I-Claim
viable I-Claim
treatment I-Claim
option I-Claim
for I-Claim
cancer I-Claim
survivors I-Claim
experiencing I-Claim
insomnia I-Claim
. I-Claim

to O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single O
- O
agent O
gemcitabine O
as O
first O
- O
line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O

patients O
with O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
1 O
, O
000 O
mg O
/ O
m2 O
and O
cisplatin O
50 O
mg O
/ O
m2 O
given O
on O
days O
1 O
and O
15 O
of O
a O
4 O
- O
week O
cycle O
( O
gemcis O
arm O
) O
or O
gemcitabine O
alone O
at O
a O
dose O
of O
1 O
, O
000 O
mg O
/ O
m2 O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
a O
4 O
- O
week O
regimen O
( O
gem O
arm O
) O
. O

the O
primary O
end O
point O
was O
overall O
survival O
"""" O
; O
"""" O
secondary O
end O
points O
were O
progression O
- O
free O
survival O
, O
response O
rate O
, O
safety O
, O
and O
quality O
of O
life O
. O

one O
hundred O
ninety O
- O
five O
patients O
were O
enrolled O
and O
showed O
baseline O
characteristics O
well O
balanced O
between O
treatment O
arms O
. O

combination B-Premise
treatment I-Premise
in I-Premise
the I-Premise
gemcis I-Premise
arm I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
prolonged I-Premise
median I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
5 I-Premise
. I-Premise
3 I-Premise
months I-Premise
v I-Premise
3 I-Premise
. I-Premise
1 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
75 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
053 I-Premise
) I-Premise
. I-Premise

also B-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
superior I-Premise
for I-Premise
patients I-Premise
treated I-Premise
in I-Premise
the I-Premise
gemcis I-Premise
arm I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
gem I-Premise
arm I-Premise
( I-Premise
7 I-Premise
. I-Premise
5 I-Premise
v I-Premise
6 I-Premise
. I-Premise
0 I-Premise
months I-Premise
) I-Premise
, I-Premise
an B-Premise
advantage I-Premise
which I-Premise
did I-Premise
not I-Premise
, I-Premise
however I-Premise
, I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
80 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
15 I-Premise
) I-Premise
. I-Premise

tumor B-Premise
response I-Premise
rates I-Premise
were I-Premise
comparable I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
10 I-Premise
. I-Premise
2 I-Premise
% I-Premise
v I-Premise
8 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
. I-Premise

the B-Premise
rate I-Premise
of I-Premise
stable I-Premise
disease I-Premise
was I-Premise
, I-Premise
however I-Premise
, I-Premise
greater I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
( I-Premise
60 I-Premise
. I-Premise
2 I-Premise
% I-Premise
v I-Premise
40 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. O

grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
hematologic I-Premise
toxicity I-Premise
did I-Premise
not I-Premise
exceed I-Premise
15 I-Premise
% I-Premise
in I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

these B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every I-Claim
- I-Claim
2 I-Claim
- I-Claim
weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim

median B-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
were I-Claim
more I-Claim
favorable I-Claim
in I-Claim
the I-Claim
combination I-Claim
arm I-Claim
as I-Claim
compared I-Claim
with I-Claim
gemcitabine I-Claim
alone I-Claim
, I-Claim
although B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
attain I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

extracellular O
adenosine O
5 O
' O
- O
triphosphate O
( O
atp O
) O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
biologic O
processes O
, O
including O
neurotransmission O
, O
muscle O
contraction O
, O
and O
liver O
glucose O
metabolism O
, O
via O
purinergic O
receptors O
. O

in B-Claim
nonrandomized I-Claim
studies I-Claim
involving I-Claim
patients I-Claim
with I-Claim
different I-Claim
tumor I-Claim
types I-Claim
including I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
, I-Claim
atp I-Claim
infusion I-Claim
appeared I-Claim
to I-Claim
inhibit I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
deterioration I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
and I-Claim
performance I-Claim
status I-Claim
. I-Claim

we O
conducted O
a O
randomized O
clinical O
trial O
to O
evaluate O
the O
effects O
of O
atp O
in O
patients O
with O
advanced O
nsclc O
( O
stage O
iiib O
or O
iv O
) O
. O

fifty O
- O
eight O
patients O
were O
randomly O
assigned O
to O
receive O
either O
10 O
intravenous O
30 O
- O
hour O
atp O
infusions O
, O
with O
the O
infusions O
given O
at O
- O
2 O
to O
4 O
- O
week O
intervals O
, O
or O
no O
atp O
. O

outcome O
parameters O
were O
assessed O
every O
4 O
weeks O
until O
28 O
weeks O
. O

between O
- O
group O
differences O
were O
tested O
for O
statistical O
significance O
by O
use O
of O
repeated O
- O
measures O
analysis O
, O
and O
reported O
p O
values O
are O
two O
- O
sided O
. O

twenty O
- O
eight O
patients O
were O
allocated O
to O
receive O
atp O
treatment O
and O
30 O
received O
no O
atp O
. O

mean B-Premise
weight I-Premise
changes I-Premise
per I-Premise
4 I-Premise
- I-Premise
week I-Premise
period I-Premise
were I-Premise
- I-Premise
1 I-Premise
. I-Premise
0 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
5 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
5 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
0 I-Premise
. I-Premise
2 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
2 I-Premise
to I-Premise
+ I-Premise
0 I-Premise
. I-Premise
6 I-Premise
) I-Premise
in I-Premise
the I-Premise
atp I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise

serum B-Premise
albumin I-Premise
concentration I-Premise
declined I-Premise
by I-Premise
- I-Premise
1 I-Premise
. I-Premise
2 I-Premise
g I-Premise
/ I-Premise
l I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
2 I-Premise
. I-Premise
0 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0 I-Premise
. I-Premise
0 I-Premise
g I-Premise
/ I-Premise
l I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
3 I-Premise
to I-Premise
+ I-Premise
0 I-Premise
. I-Premise
3 I-Premise
) I-Premise
in I-Premise
the I-Premise
atp I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise

elbow B-Premise
flexor I-Premise
muscle I-Premise
strength I-Premise
declined I-Premise
by I-Premise
- I-Premise
5 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
9 I-Premise
. I-Premise
6 I-Premise
% I-Premise
to I-Premise
- I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0 I-Premise
. I-Premise
0 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
to I-Premise
+ I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
atp I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

a B-Premise
similar I-Premise
pattern I-Premise
was I-Premise
observed I-Premise
for I-Premise
knee I-Premise
extensor I-Premise
muscles I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise

the B-Premise
effects I-Premise
of I-Premise
atp I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
0002 I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
0001 I-Premise
, I-Premise
and I-Premise
p I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
atp I-Premise
versus I-Premise
no I-Premise
atp I-Premise
) I-Premise
. I-Premise

qol B-Premise
score I-Premise
changes I-Premise
per I-Premise
4 I-Premise
- I-Premise
week I-Premise
period I-Premise
in I-Premise
the I-Premise
atp I-Premise
group I-Premise
showed I-Premise
overall I-Premise
less I-Premise
deterioration I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
- I-Premise
physical I-Premise
scores I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
2 I-Premise
% I-Premise
versus I-Premise
- I-Premise
2 I-Premise
. I-Premise
4 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
functional I-Premise
scores I-Premise
( I-Premise
+ I-Premise
0 I-Premise
. I-Premise
4 I-Premise
% I-Premise
versus I-Premise
- I-Premise
5 I-Premise
. I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
psychologic I-Premise
scores I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
7 I-Premise
% I-Premise
versus I-Premise
- I-Premise
2 I-Premise
. I-Premise
4 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
11 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
overall I-Premise
qol I-Premise
score I-Premise
( I-Premise
+ I-Premise
0 I-Premise
. I-Premise
1 I-Premise
% I-Premise
versus I-Premise
- I-Premise
3 I-Premise
. I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise

this O
randomized O
trial O
demonstrates O
that O
atp B-Claim
has I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
weight I-Claim
, I-Claim
muscle I-Claim
strength I-Claim
, I-Claim
and I-Claim
qol I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim

abiraterone B-Claim
acetate I-Claim
plus I-Claim
prednisone I-Claim
significantly I-Claim
improves I-Claim
radiographic I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
in I-Claim
asymptomatic I-Claim
or I-Claim
mildly I-Claim
symptomatic I-Claim
, I-Claim
chemotherapy I-Claim
- I-Claim
naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration I-Claim
- I-Claim
resistant I-Claim
prostate I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

we O
describe O
analyses O
of O
data O
for O
patient O
- O
reported O
pain O
and O
functional O
status O
in O
a O
preplanned O
interim O
analysis O
of O
a O
phase O
3 O
trial O
. O

between O
april O
28 O
, O
2009 O
, O
and O
june O
23 O
, O
2010 O
, O
patients O
with O
progressive O
, O
metastatic O
castration O
- O
resistant O
prostate O
cancer O
were O
enrolled O
into O
a O
multinational O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
. O

patients O
were O
eligible O
if O
they O
were O
asymptomatic O
( O
score O
of O
0 O
or O
1 O
on O
item O
three O
of O
the O
brief O
pain O
inventory O
short O
form O
[ O
bpi O
- O
sf O
] O
questionnaire O
) O
or O
mildly O
symptomatic O
( O
score O
of O
2 O
or O
3 O
) O
and O
had O
not O
previously O
received O
chemotherapy O
. O

patients O
were O
randomly O
assigned O
( O
1 O
: O
1 O
) O
to O
receive O
oral O
abiraterone O
( O
1 O
g O
daily O
) O
plus O
prednisone O
( O
5 O
mg O
twice O
daily O
) O
or O
placebo O
plus O
prednisone O
in O
continuous O
4 O
- O
week O
cycles O
. O

pain O
was O
assessed O
with O
the O
bpi O
- O
sf O
questionnaire O
, O
and O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
with O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
prostate O
( O
fact O
- O
p O
) O
questionnaire O
. O

we O
analysed O
data O
with O
prespecified O
criteria O
for O
clinically O
meaningful O
pain O
progression O
and O
deterioration O
in O
hrqol O
. O

all O
patients O
who O
underwent O
randomisation O
were O
included O
in O
analyses O
. O

1088 O
patients O
underwent O
randomisation O
: O
546 O
were O
assigned O
to O
abiraterone O
plus O
prednisone O
and O
542 O
to O
placebo O
plus O
prednisone O
. O

at O
the O
time O
of O
the O
second O
prespecified O
interim O
analysis O
, O
median O
follow O
- O
up O
was O
22 O
Â· O
2 O
months O
( O
iqr O
20 O
Â· O
2 O
- O
24 O
Â· O
8 O
) O
. O

median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
mean I-Premise
pain I-Premise
intensity I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26 I-Premise
Â· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
19 I-Premise
Â· I-Premise
3 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
18 I-Premise
Â· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
14 I-Premise
Â· I-Premise
9 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
0 I-Premise
Â· I-Premise
82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
Â· I-Premise
67 I-Premise
- I-Premise
1 I-Premise
Â· I-Premise
00 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
Â· I-Premise
0490 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
pain I-Premise
interference I-Premise
with I-Premise
daily I-Premise
activities I-Premise
( I-Premise
10 I-Premise
Â· I-Premise
3 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
9 I-Premise
Â· I-Premise
3 I-Premise
- I-Premise
13 I-Premise
Â· I-Premise
0 I-Premise
] I-Premise
vs I-Premise
7 I-Premise
Â· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
6 I-Premise
Â· I-Premise
4 I-Premise
- I-Premise
8 I-Premise
Â· I-Premise
6 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hr I-Premise
0 I-Premise
Â· I-Premise
79 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
Â· I-Premise
67 I-Premise
- I-Premise
0 I-Premise
Â· I-Premise
93 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
Â· I-Premise
005 I-Premise
) I-Premise
. I-Premise

median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
worst I-Premise
pain I-Premise
was I-Premise
also I-Premise
longer I-Premise
with I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26 I-Premise
Â· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
19 I-Premise
Â· I-Premise
4 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
with I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
19 I-Premise
Â· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
16 I-Premise
Â· I-Premise
6 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
, I-Premise
but I-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
significant I-Premise
( I-Premise
hr I-Premise
0 I-Premise
Â· I-Premise
85 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
Â· I-Premise
69 I-Premise
- I-Premise
1 I-Premise
Â· I-Premise
04 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
Â· I-Premise
109 I-Premise
) I-Premise
. I-Premise

median B-Premise
time I-Premise
to I-Premise
hrqol I-Premise
deterioration I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
fact I-Premise
- I-Premise
p I-Premise
total I-Premise
score I-Premise
( I-Premise
12 I-Premise
Â· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
11 I-Premise
Â· I-Premise
1 I-Premise
- I-Premise
14 I-Premise
Â· I-Premise
0 I-Premise
] I-Premise
vs I-Premise
8 I-Premise
Â· I-Premise
3 I-Premise
months I-Premise
[ I-Premise
7 I-Premise
Â· I-Premise
4 I-Premise
- I-Premise
10 I-Premise
Â· I-Premise
6 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hr I-Premise
0 I-Premise
Â· I-Premise
78 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
Â· I-Premise
66 I-Premise
- I-Premise
0 I-Premise
Â· I-Premise
92 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
Â· I-Premise
003 I-Premise
) I-Premise
and I-Premise
by I-Premise
the I-Premise
score I-Premise
on I-Premise
its I-Premise
prostate I-Premise
- I-Premise
cancer I-Premise
- I-Premise
specific I-Premise
subscale I-Premise
( I-Premise
11 I-Premise
Â· I-Premise
1 I-Premise
months I-Premise
[ I-Premise
8 I-Premise
Â· I-Premise
6 I-Premise
- I-Premise
13 I-Premise
Â· I-Premise
8 I-Premise
] I-Premise
vs I-Premise
5 I-Premise
Â· I-Premise
8 I-Premise
months I-Premise
[ I-Premise
5 I-Premise
Â· I-Premise
5 I-Premise
- I-Premise
8 I-Premise
Â· I-Premise
3 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hr I-Premise
0 I-Premise
Â· I-Premise
70 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
Â· I-Premise
60 I-Premise
- I-Premise
0 I-Premise
Â· I-Premise
83 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
Â· I-Premise
0001 I-Premise
) I-Premise
. I-Premise

abiraterone B-Claim
plus I-Claim
prednisone I-Claim
delays I-Claim
patient I-Claim
- I-Claim
reported I-Claim
pain I-Claim
progression I-Claim
and I-Claim
hrqol I-Claim
deterioration I-Claim
in I-Claim
chemotherapy I-Claim
- I-Claim
naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration I-Claim
- I-Claim
resistant I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

these B-Claim
results I-Claim
provide I-Claim
further I-Claim
support I-Claim
for I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
abiraterone I-Claim
in I-Claim
this I-Claim
population I-Claim
. I-Claim

postoperative B-Claim
adjuvant I-Claim
chemoradiation I-Claim
treatment I-Claim
after I-Claim
curative I-Claim
resection I-Claim
for I-Claim
rectal I-Claim
cancer I-Claim
was I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
recurrence I-Claim
and I-Claim
improve I-Claim
a I-Claim
survival I-Claim
rate I-Claim
. I-Claim

intravenous B-Claim
5 I-Claim
- I-Claim
fluorouracil I-Claim
( I-Claim
5 I-Claim
- I-Claim
fu I-Claim
) I-Claim
and I-Claim
leucovorin I-Claim
has I-Claim
been I-Claim
a I-Claim
mainstay I-Claim
of I-Claim
chemotherapy I-Claim
, I-Claim
but O
oral B-Claim
5 I-Claim
- I-Claim
fu I-Claim
derivatives I-Claim
have I-Claim
been I-Claim
shown I-Claim
a I-Claim
comparable I-Claim
antitumor I-Claim
activity I-Claim
. I-Claim

intravenous O
5 O
- O
fu O
and O
oral O
doxifluridine O
were O
compared O
with O
respect O
to O
therapeutic O
efficacy O
, O
drug O
toxicity O
, O
and O
quality O
of O
life O
. O

a O
total O
of O
166 O
patients O
were O
randomized O
to O
receive O
intravenous O
5 O
- O
fu O
( O
450 O
mg O
/ O
m2 O
/ O
day O
) O
or O
oral O
doxifluridine O
( O
900 O
mg O
/ O
m2 O
/ O
day O
) O
in O
combination O
with O
leucovorin O
( O
20 O
mg O
/ O
m2 O
/ O
day O
) O
for O
depth O
of O
invasion O
, O
nodal O
status O
, O
metastasis O
( O
tnm O
) O
stage O
ii O
and O
iii O
patients O
between O
october O
1997 O
and O
february O
1999 O
. O

consecutive O
daily O
intravenous O
infusion O
for O
5 O
days O
per O
every O
month O
for O
a O
total O
of O
12 O
cycles O
( O
iv O
arm O
, O
n O
= O
74 O
) O
and O
oral O
doxifluridine O
daily O
for O
3 O
weeks O
and O
1 O
week O
rest O
for O
a O
total O
of O
12 O
cycles O
( O
oral O
arm O
, O
n O
= O
92 O
) O
. O

drug O
toxicity O
and O
quality O
of O
life O
were O
observed O
. O

quality O
of O
life O
was O
scored O
according O
to O
22 O
daily O
activity O
items O
( O
good O
, O
> O
or O
71 O
"""" O
; O
"""" O
fair O
, O
< O
70 O
"""" O
; O
"""" O
poor O
, O
< O
52 O
) O
. O

there O
was O
no O
difference O
of O
sex O
between O
two O
groups O
( O
iv O
arm O
: O
male O
/ O
female O
= O
45 O
/ O
29 O
, O
oral O
arm O
: O
male O
/ O
female O
= O
59 O
/ O
33 O
) O
. O

the O
mean O
age O
was O
52 O
. O
3 O
vs O
. O
59 O
. O
5 O
, O
respectively O
. O

there O
was O
also O
no O
difference O
of O
tnm O
stage O
distribution O
and O
type O
of O
operation O
between O
groups O
( O
p O
> O
. O
05 O
) O
. O

mean B-Premise
numbers I-Premise
of I-Premise
chemotherapy I-Premise
cycles I-Premise
were I-Premise
6 I-Premise
. I-Premise
5 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
3 I-Premise
. I-Premise
7 I-Premise
( I-Premise
iv I-Premise
arm I-Premise
) I-Premise
vs I-Premise
. I-Premise
7 I-Premise
. I-Premise
2 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
4 I-Premise
. I-Premise
3 I-Premise
( I-Premise
oral I-Premise
arm I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

the B-Premise
rate I-Premise
of I-Premise
recurrence I-Premise
was I-Premise
9 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
12 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
iv I-Premise
arm I-Premise
and I-Premise
6 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
6 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
937 I-Premise
) I-Premise
. I-Premise

local B-Premise
recurrence I-Premise
was I-Premise
2 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
stage I-Premise
iii I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
2 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
iv I-Premise
arm I-Premise
and I-Premise
1 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
stage I-Premise
ii I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
1 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

systemic B-Premise
recurrence I-Premise
was I-Premise
7 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
stage I-Premise
iii I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
9 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
iv I-Premise
arm I-Premise
and I-Premise
5 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
stage I-Premise
iii I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
5 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

the B-Premise
most I-Premise
common I-Premise
site I-Premise
of I-Premise
systemic I-Premise
recurrence I-Premise
was I-Premise
the I-Premise
liver I-Premise
. I-Premise

toxicity B-Premise
profile I-Premise
was I-Premise
as I-Premise
follows I-Premise
: I-Premise
leukopenia I-Premise
( I-Premise
30 I-Premise
/ I-Premise
74 I-Premise
vs I-Premise
. I-Premise
17 I-Premise
/ I-Premise
92 I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
21 I-Premise
/ I-Premise
74 I-Premise
vs I-Premise
. I-Premise
13 I-Premise
/ I-Premise
92 I-Premise
) I-Premise
were I-Premise
statistically I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
iv I-Premise
arm I-Premise
. I-Premise

diarrhea B-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
. I-Premise

poor B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
between I-Premise
two I-Premise
groups I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
23 I-Premise
. I-Premise
9 I-Premise
% I-Premise
vs I-Premise
. I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
15 I-Premise
. I-Premise
8 I-Premise
% I-Premise
vs I-Premise
. I-Premise
3 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
after I-Premise
chemotherapy I-Premise
. I-Premise

good B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
19 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
. I-Premise
49 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
47 I-Premise
% I-Premise
vs I-Premise
. I-Premise
72 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise

oral B-Claim
doxifluridine I-Claim
with I-Claim
leucovorin I-Claim
shows I-Claim
a I-Claim
comparable I-Claim
therapeutic I-Claim
efficacy I-Claim
to I-Claim
intravenous I-Claim
5 I-Claim
- I-Claim
fu I-Claim
regimen I-Claim
with I-Claim
high I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
postoperative I-Claim
adjuvant I-Claim
therapy I-Claim
. I-Claim

the B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim

this O
phase O
iii O
randomized O
trial O
compared O
two O
chemotherapy O
regimens O
, O
gemcitabine O
plus O
carboplatin O
and O
mitomycin O
, O
ifosfamide O
, O
and O
cisplatin O
, O
in O
chemotherapy O
- O
naive O
patients O
with O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
. O

the O
regimens O
were O
compared O
with O
regard O
to O
effects O
on O
survival O
, O
response O
rates O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

eligible O
patients O
had O
previously O
untreated O
stage O
iiib O
or O
iv O
nsclc O
suitable O
for O
cisplatin O
- O
based O
chemotherapy O
. O

randomly O
assigned O
patients O
were O
to O
receive O
four O
cycles O
, O
each O
at O
3 O
- O
week O
intervals O
, O
of O
carboplatin O
area O
under O
the O
curve O
of O
5 O
on O
day O
1 O
plus O
gemcitabine O
1 O
, O
200 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
( O
gca O
) O
or O
mitomycin O
6 O
mg O
/ O
m O
( O
2 O
) O
, O
ifosfamide O
3g O
/ O
m O
( O
2 O
) O
, O
and O
cisplatin O
50 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
( O
mic O
) O
. O

between O
february O
1999 O
and O
august O
2001 O
, O
422 O
patients O
( O
gca O
, O
n O
= O
212 O
"""" O
; O
"""" O
mic O
, O
n O
= O
210 O
) O
were O
randomly O
assigned O
in O
the O
united O
kingdom O
. O

the O
majority O
of O
patients O
received O
the O
intended O
four O
cycles O
( O
gca O
, O
64 O
% O
"""" O
; O
"""" O
mic O
, O
61 O
% O
) O
. O

there B-Premise
was I-Premise
a I-Premise
significant I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
gca I-Premise
compared I-Premise
with I-Premise
mic I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
76 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
61 I-Premise
to I-Premise
0 I-Premise
. I-Premise
93 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
. I-Premise

median B-Premise
survival I-Premise
was I-Premise
10 I-Premise
months I-Premise
with I-Premise
gca I-Premise
and I-Premise
7 I-Premise
. I-Premise
6 I-Premise
months I-Premise
with I-Premise
mic I-Premise
( I-Premise
difference I-Premise
, I-Premise
2 I-Premise
. I-Premise
4 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
0 I-Premise
to I-Premise
4 I-Premise
. I-Premise
0 I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
was I-Premise
40 I-Premise
% I-Premise
with I-Premise
gca I-Premise
and I-Premise
30 I-Premise
% I-Premise
with I-Premise
mic I-Premise
( I-Premise
difference I-Premise
, I-Premise
10 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
3 I-Premise
% I-Premise
to I-Premise
18 I-Premise
% I-Premise
) I-Premise
. I-Premise

overall B-Premise
response I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
42 I-Premise
% I-Premise
for I-Premise
gca I-Premise
v I-Premise
41 I-Premise
% I-Premise
for I-Premise
mic I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
84 I-Premise
) I-Premise
. I-Premise

more B-Premise
thrombocytopenia I-Premise
occurred I-Premise
with I-Premise
gca I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admission I-Premise
or I-Premise
fatality I-Premise
. I-Premise

gca B-Premise
caused I-Premise
less I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
constipation I-Premise
, I-Premise
and I-Premise
alopecia I-Premise
and I-Premise
was I-Premise
associated I-Premise
with I-Premise
fewer I-Premise
admissions I-Premise
for I-Premise
administration I-Premise
and I-Premise
better I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

in B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
, I-Claim
gca I-Claim
chemotherapy I-Claim
was I-Claim
shown I-Claim
to I-Claim
be I-Claim
a I-Claim
better I-Claim
- I-Claim
tolerated I-Claim
treatment I-Claim
that I-Claim
conferred I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
mic I-Claim
. I-Claim

to O
perform O
a O
randomized O
trial O
comparing O
70 O
and O
80 O
gy O
radiotherapy O
for O
prostate O
cancer O
. O

a O
total O
of O
306 O
patients O
with O
localized O
prostate O
cancer O
were O
randomized O
. O

no O
androgen O
deprivation O
was O
allowed O
. O

the O
primary O
endpoint O
was O
biochemical O
relapse O
according O
to O
the O
modified O
1997 O
- O
american O
society O
for O
therapeutic O
radiology O
and O
oncology O
and O
phoenix O
definitions O
. O

toxicity O
was O
graded O
using O
the O
radiation O
therapy O
oncology O
group O
1991 O
criteria O
and O
the O
late O
effects O
on O
normal O
tissues O
- O
subjective O
, O
objective O
, O
management O
, O
analytic O
scales O
( O
lent O
- O
soma O
) O
scales O
. O

the O
patients O
' O
quality O
of O
life O
was O
scored O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
30 O
- O
item O
cancer O
- O
specific O
and O
25 O
- O
item O
prostate O
- O
specific O
modules O
. O

the O
median O
follow O
- O
up O
was O
61 O
months O
. O

according O
to O
the O
1997 O
- O
american O
society O
for O
therapeutic O
radiology O
and O
oncology O
definition O
, O
the O
5 O
- O
year O
biochemical O
relapse O
rate O
was O
39 O
% O
and O
28 O
% O
in O
the O
- O
70 O
and O
80 O
- O
gy O
arms O
, O
respectively O
( O
p O
= O
. O
036 O
) O
. O

using O
the O
phoenix O
definition O
, O
the O
5 O
- O
year O
biochemical O
relapse O
rate O
was O
32 O
% O
and O
23 O
. O
5 O
% O
, O
respectively O
( O
p O
= O
. O
09 O
) O
. O

the O
subgroup O
analysis O
showed O
a O
better O
biochemical O
outcome O
for O
the O
higher O
dose O
group O
with O
an O
initial O
prostate O
- O
specific O
antigen O
level O
> O
15 O
ng O
/ O
ml O
. O

at O
the O
last O
follow O
- O
up O
date O
, O
26 O
patients O
had O
died O
, O
10 O
of O
their O
disease O
and O
none O
of O
toxicity O
, O
with O
no O
differences O
between O
the O
two O
arms O
. O

according B-Premise
to I-Premise
the I-Premise
radiation I-Premise
therapy I-Premise
oncology I-Premise
group I-Premise
scale I-Premise
, I-Premise
the I-Premise
grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
rectal I-Premise
toxicity I-Premise
rate I-Premise
was I-Premise
14 I-Premise
% I-Premise
and I-Premise
19 I-Premise
. I-Premise
5 I-Premise
% I-Premise
for I-Premise
the I-Premise
- I-Premise
70 I-Premise
and I-Premise
80 I-Premise
- I-Premise
gy I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
22 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

the B-Premise
grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
urinary I-Premise
toxicity I-Premise
was I-Premise
10 I-Premise
% I-Premise
at I-Premise
70 I-Premise
gy I-Premise
and I-Premise
17 I-Premise
. I-Premise
5 I-Premise
% I-Premise
at I-Premise
80 I-Premise
gy I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
046 I-Premise
) I-Premise
. I-Premise

similar B-Premise
results I-Premise
were I-Premise
observed I-Premise
using I-Premise
the I-Premise
lent I-Premise
- I-Premise
soma I-Premise
scale I-Premise
. I-Premise

bladder B-Premise
toxicity I-Premise
was I-Premise
more I-Premise
frequent I-Premise
at I-Premise
80 I-Premise
gy I-Premise
than I-Premise
at I-Premise
70 I-Premise
gy I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
039 I-Premise
) I-Premise
. I-Premise

the B-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
questionnaire I-Premise
results I-Premise
before I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
were I-Premise
available I-Premise
for I-Premise
103 I-Premise
patients I-Premise
with I-Premise
no I-Premise
differences I-Premise
found I-Premise
between I-Premise
the I-Premise
- I-Premise
70 I-Premise
and I-Premise
80 I-Premise
- I-Premise
gy I-Premise
arms I-Premise
. I-Premise

high B-Claim
- B-Claim
dose B-Claim
radiotherapy I-Claim
provided I-Claim
a I-Claim
better I-Claim
5 I-Claim
- I-Claim
year I-Claim
biochemical I-Claim
outcome I-Claim
with I-Claim
slightly I-Claim
greater I-Claim
toxicity I-Claim
. I-Claim

several O
multicomponent O
regimens O
have O
been O
reported O
to O
be O
useful O
in O
advanced O
androgen O
- O
independent O
prostate O
cancer O
. O

we O
used O
a O
randomized O
phase O
ii O
design O
to O
evaluate O
and O
compare O
two O
such O
regimens O
. O

patients O
were O
accrued O
primarily O
in O
the O
community O
setting O
. O

patients O
with O
progressive O
, O
androgen O
- O
independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole O
/ O
doxorubicin O
alternating O
with O
vinblastine O
/ O
estramustine O
( O
ka O
/ O
ve O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
tee O
) O
. O

